Scholar Rock Highlights 2025 Strategic Priorities

CAMBRIDGE, Mass., January 08, 2025–Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2025.

This article was originally published here.